GlaxoSmithKline’s immunotherapy MAGE-A3 cancer drug has failed among non-small cell lung cancer patients in a Phase III clinical trial. The company announced Thursday that the drug failed to significantly extend disease-free survival among patients its target groups. Bloomberg notes that this is the second time the drug has failed among advanced cancer patients.
The company said it is will continue with a third endpoint that was part of this trial—one that focuses on a subset of patients (those who are MAGE-A3 positive)—who may benefit from the treatment.
GSK said it is also continuing with another clinical study using this same drug, but in melanoma patients.
